Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Crespo

Showing results (251-260 of 365) with videos related to

Pageof 37
Sort By:
Revista Espanola De Enfermedades Digestivas|February 28, 2019
An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesityEsther Nistal, Luis E Sáenz de Miera, María Ballesteros Pomar, et al.
United European Gastroenterology Journal|August 5, 2024
One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk populationPaula Iruzubieta, Rebeca Mayo, Itziar Mincholé, et al.
Journal of Viral Hepatitis|November 23, 2019
Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in SpainJavier Crespo, Antonio Cuadrado, Christie Perelló, et al.
Gastroenterologia Y Hepatologia|May 15, 2022
AEEH «Consensus about detection and referral of hidden prevalent liver diseases»Manuel Romero-Gómez, Rocío Aller, Javier Ampuero, et al.
United European Gastroenterology Journal|November 28, 2023
No evidence of association between inherited thrombophilia and increased risk of liver fibrosisIranzu Ezcurra, Ángela Puente, Antonio Cuadrado, et al.
Gastroenterology|August 8, 2006
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatmentJosé M Sánchez-Tapias, Moisés Diago, Pedro Escartín, et al.
Scientific Reports|May 11, 2021
Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at homePaula Iruzubieta, Tatiana Fernández-Lanas, Laura Rasines, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 1, 2022
Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histologyJosé L Calleja, Jesús Rivera-Esteban, Rocío Aller, et al.
Cells|December 23, 2022
Impact of Liver Inflammation on Bile Acid Side Chain Shortening and AmidationMarta Alonso-Peña, Ricardo Espinosa-Escudero, Heike M Hermanns, et al.
Adicciones|October 6, 2022
Certification program of Addiction Centres for hepatitis C virus elimination in Spain. HepCelentes ProjectJoan Colom, Marta Torrens, Ángeles Rodríguez-Cejas, et al.
Pageof 37

Showing results (251-260 of 365) with videos related to

Sort By:
Pageof 37
Revista Espanola De Enfermedades Digestivas|February 28, 2019
An altered fecal microbiota profile in patients with non-alcoholic fatty liver disease (NAFLD) associated with obesityEsther Nistal, Luis E Sáenz de Miera, María Ballesteros Pomar, et al.
United European Gastroenterology Journal|August 5, 2024
One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk populationPaula Iruzubieta, Rebeca Mayo, Itziar Mincholé, et al.
Journal of Viral Hepatitis|November 23, 2019
Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in SpainJavier Crespo, Antonio Cuadrado, Christie Perelló, et al.
Gastroenterologia Y Hepatologia|May 15, 2022
AEEH «Consensus about detection and referral of hidden prevalent liver diseases»Manuel Romero-Gómez, Rocío Aller, Javier Ampuero, et al.
United European Gastroenterology Journal|November 28, 2023
No evidence of association between inherited thrombophilia and increased risk of liver fibrosisIranzu Ezcurra, Ángela Puente, Antonio Cuadrado, et al.
Gastroenterology|August 8, 2006
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatmentJosé M Sánchez-Tapias, Moisés Diago, Pedro Escartín, et al.
Scientific Reports|May 11, 2021
Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at homePaula Iruzubieta, Tatiana Fernández-Lanas, Laura Rasines, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 1, 2022
Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histologyJosé L Calleja, Jesús Rivera-Esteban, Rocío Aller, et al.
Cells|December 23, 2022
Impact of Liver Inflammation on Bile Acid Side Chain Shortening and AmidationMarta Alonso-Peña, Ricardo Espinosa-Escudero, Heike M Hermanns, et al.
Adicciones|October 6, 2022
Certification program of Addiction Centres for hepatitis C virus elimination in Spain. HepCelentes ProjectJoan Colom, Marta Torrens, Ángeles Rodríguez-Cejas, et al.
Pageof 37